Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

NCT01679964 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

107

Enrollment

INDIV

Sponsor class

Conditions

HIV Infection
Adverse Drug Reaction
Quality of Life

Interventions

DRUG: Raltegravir switch

Sponsor

Lin, Hsi-Hsun, M.D.